News Headlines Article

Gilead’s 2014 profit margin nears 50%, fueled by hep C drugs
Modern Healthcare

Gilead Sciences, the Foster City, Calif.-based drugmaker, said sales of its blockbuster hepatitis C duo topped $3.8 billion in the fourth quarter of 2014, fueling quarterly revenue that doubled to $7.3 billion and $3.5 billion in profits.

Gilead’s Sovaldi, which has been on the U.S. market for 13 months, generated $1.7 billion in sales in the fourth quarter. It brought in $10.3 billion in sales in one year, with $8.5 billion coming from the U.S. market. Harvoni, also developed by Gilead, received approval in October from the Food and Drug Administration and has already reported $2.1 billion in sales.